Theralase Technologies Inc. V.TLT

RE:RE:Sorry wrong Link last post :-(

[CancerSlayer]

wildbird1 wrote:

Oden6570 wrote: Non-Muscle Invasive Bladder Cancer Market Set to Reach New Heights Amidst Growing Pipeline and Research Initiatives | DelveInsight

Oden6570.

In the article you provided there is a sub-article.

Sample page for NMIBC Market Outlook Report

It is mentioned that in Japan Adstiladrin is expected to capture the largest market shares for BCG resistant patients.
From what I read on this board Adstiladrin is a repeated treatment has contraindications and has a much lower CR% at 450 days than TLT treatment.
Adstiladrin is absolutely not in the same class as TLT treatment.
Let's be clear on something Japan is a very very small market, but that is not the point, the point is that if Adstiladrin is the best treatment they can offer to BCG resistant patients, then there is an urgent need for a better alternative like TLT treatment.

The same apply to other much bigger market like US.

In the US, it has been reported (per a web-based survey of urologic oncologists) that intravesical Gem/Doce (chemo) is also commonly used as a first-line bladder-sparing treatment (BST) for BCG-unresponsive NMIBC.  However, there were significant obstacles reported to prescribing this treatment, which included clinical workflow issues (i.e. frequent dosing = 6 weekly doses, followed by monthly maintenance), challenges with supply & cost.

Re: Adstiladrin, it had a 12 month DOR rate of 24% (vs our ~27% 12 month DOR rate, which has potential to increase).  As a viral vector gene-based therapy, Adstiladrin cannot be used in immunocompromised/deficient patients & has special handling requirements (frozen suspension with specific thawing requirements).  It also requires more treatments than our ACT....from what I can gather, a complete treatment course would involve a treatment every 3 months for up to 4 years.

In August 2023, a global group of bladder cancer experts made recommendations (which were updated) that includes the above two treatments as the currently preferred first-line (non-BCG) bladder-sparing treatments.  There was one additional recommended BST that included BCG as a combo treatment.

So, we currently have a total of 3 "globally recommended" bladder-sparing treatment options, & notably all of these options are burdened with significant barriers to long-term efficacy success (when compared to bladder removal)....All imo.

Holding tightly...good luck.